| Name | Title | Contact Details |
|---|
Hardy Diagnostics (Main) HQ is a Santa Maria, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medical Tracking Solutions, a team of medical device industry experts, developed iTraycer to meet the day-to-day challenges of medical device companies. iTraycer is a comprehensive inventory management system that provides real-time tracking of medical devices and biologics – visible by part, lot, and serial numbers – from manufacturer to patient. The system`s multifunctional software facilitates communication and collaboration across the enterprise and enables companies to make critical, fact-based decisions with real-time information. And, iTraycer ensures compliance by addressing the traceability requirements of Unique Device Identification (UDI) regulations.
GlySens Incorporated is a privately held corporation devoted to developing the world`s first truly long term continuous glucose monitoring system. Our goal: to enable easy, unobtrusive, worry-free diabetes control that empowers users by providing the information they need to optimize care, while freeing them to live life on their own terms.
TVA Medical, Inc. is a medical device company developing innovative, minimally invasive therapies for treatment of End-Stage Renal Disease (ESRD). The company was founded by Dr. William Cohn in partnership with Sante Ventures, a life sciences venture capital firm based in Austin, TX.
Motif Neurotech is a clinical-stage company leading the development of minimally invasive neuromodulation therapeutics for mental health. The company`s lead product, for treatment resistant depression (TRD), is a miniature implant that is designed to treat TRD by increasing activity in the prefrontal cortex. Studies over 20 years show stimulation of the pre-frontal cortex effectively treats treatment resistant depression without the side effects of anti-depressants. However, existing brain stimulation treatments like transcranial magnetic stimulation (TMS) can be expensive and challenging for patients to access, with daily treatments required for six weeks that may need to be repeated. Human and large animal studies show Motif`s prototype stimulates target brain areas like TMS, and the company is preparing to begin clinical trials of their first chronic implants in 2025. Motif`s implant is enabled by patent-pending wireless magnetoelectric power transfer developed at Rice University. Motif`s founders and key team members are clinical, medical device and academic experts with over 5,000 surgical procedures and decades of medical device experience.